Matinas BioPharma Holdings, Inc. Matinas BioPharma Holdings, Inc.

close
  • Home
  • LYPDISO™
    • LYPDISO™ Overview
    • Omega-3 Fatty Acids
  • LNC Technology
    • LNC Platform
    • MAT2203
    • MAT2501
  • About Us
    • Company Overview
    • Leadership
    • News
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Investors Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Company Info Overview
    • Executive Team
    • Presentations
    • Contacts
  • Financial Info
    • Financial Info Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
News & Events

News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Jun 19, 2018 8:00am EDT

Matinas BioPharma Announces Pricing of $8.0 Million Public Offering

Jun 12, 2018 8:00am EDT

Matinas BioPharma to Present at the 20th ICHS Symposium on Infections in the Immunocompromised Host

Jun 06, 2018 7:35am EDT

Matinas BioPharma to Present Preclinical Data at ASM Microbe 2018 Further Demonstrating the Broad Utility of its LNC Platform

May 10, 2018 7:05am EDT

Matinas BioPharma Reports First Quarter 2018 Financial Results and Provides Corporate Update

May 07, 2018 8:05am EDT

Matinas BioPharma to Host Quarterly Update Conference Call

May 01, 2018 8:05am EDT

Matinas BioPharma Selected to Present at the BioNJ Eighth Annual BioPartnering Conference

Apr 19, 2018 8:05am EDT

Matinas BioPharma to Present Positive Preclinical Data of MAT2203 at the 28th European Congress of Clinical Microbiology and Infectious Disease

Mar 26, 2018 4:45pm EDT

Matinas BioPharma Reports 2017 Financial Results

Mar 16, 2018 5:00pm EDT

Matinas BioPharma Appoints Jerome D. Jabbour as Chief Executive Officer and Provides Corporate Update

Mar 15, 2018 8:00am EDT

Matinas BioPharma to Present at the Oppenheimer 28th Annual Healthcare Conference

RSS
  • Prev
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13
    • ...20
    Next
    Matinas BioPharma Holdings, Inc.

    Science

    • LYPDISO™ (MAT9001)
    • MAT2203
    • MAT2501
    • LNC PLATFORM

    Investors

    • COMPANY PROFILE
    • STOCK DATA
    • ANALYST COVERAGE
    • GOVERNANCE
    • PRESS RELEASES
    • EVENTS
    • PRESENTATIONS
    • SEC FILINGS

    Company

    • OVERVIEW
    • OUR TEAM
    • NEWS
    • CAREERS
    • CONTACT US

    Register for updates

    Follow Us

    LinkedIn facebook twitter
    © 2021 Matinas BioPharma Holdings, Inc. All Rights Reserved.